Anti-Mouse CD70 (Clone TAN 1-7) - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Mouse

Immunogen

Recombinant mouse CD70 (extracellular domain, aa residues 41-195)

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893831

Applications and Recommended Usage?
Quality Tested by Leinco

FC

ELISA

Other Applications Reported In Literature ?

B
IF

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone TAN1-7 monoclonal antibody recognizes a direct epitope on mouse CD70 and capable of blocking the CD70-CD27 interaction involved in B and T cell activation.

Antigen Distribution

CD70 is expressed on activated T cells, B cells, and dendritic cells.

Background

CD70 antibody, TAN1-7, recognizes CD70, a type II membrane protein and member of the TNF family. CD70 is the ligand for the T cell costimulatory receptor CD27 (also known as TNFRSF27)¹ and is expressed on activated T cells, B cells, and dendritic cells (DCs)^{1, 2}. Ligation of CD27 on T cells with CD70 on DCs provides costimulatory signals and promotes CD4 and CD8 T cell activation³, differentiation⁴, and survival^{5, 6}. CD70 also regulates B cell activation and antibody production⁷ and enhances natural killer (NK) cell survival and function⁸. CD70 is constitutively expressed in several hematological and solid tumors and increases the proliferation and survival of tumor cells and regulatory T cells (Tregs), suggesting it may be an effective therapeutic target^9-13. Increased levels of CD70 are also associated with autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)^{14, 15}.

Antigen Details

Protein

CD70

PubMed

CD70

NCBI Gene Bank ID

970

UniProt.org

UniProtKB - P32970 (CD70_HUMAN)t

Research Area

Costimulatory Molecules

.

Immunology

References & Citations

1. R. A. van Lier., et al. (1997) J. Immunol. 159(10):4959-65

2. R. A. van Lier. et al. (2003) J. Immunol. 170(1):33-40

3. Hintzen, R. Q. et al. (1995) J. Immunol. 154, 2612–2623

4. Soares, H. et al. (2007) J. Exp. Med. 204, 1095–1106

5. Hendriks, J. et al. (2000) Nat. Immunol.1, 433–440

6. Hendriks, J., Xiao, Y. & Borst, J. (2003) J. Exp. Med.198, 1369–1380

7. van Oers MH., et al. (2004) J Immunol. 15; 173(6):3901-8.
8. Ochsenbein AF., et al. (2017) 20; 130(3):297-309

9. Ansell SM., et al. (2007) Blood. 110:2537–2544

10. Doronina SO., et al. (2006) Cancer Res. 66:2328–2337

11. Weller M., et al. (2002) Cancer Res. 62:2592–2599

12. Held-Feindt, J. & R. Mentlein. (2002) Int. J. Cancer 98:352

13. Chiodi F., et al. (2005) Exp Hematol. 33:1500–1507

14. Han, B. K. et al. (2005) Lupus. 14, 598–606

15. Park, J. K. et al. (2014) Rheumatology. 53, 1896–1900

Technical Protocols